[1]高四书 王龙 华飞.晚期糖基化终末产物与多囊卵巢综合征的关系[J].国际内分泌代谢杂志,2018,38(04):279-283.[doi:10.3760/cma.j.issn.1673-4157.2018.04.015]
 Gao Sishu,Wang Long,Hua Fei.Relationship between advanced glycation end-products and polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2018,38(04):279-283.[doi:10.3760/cma.j.issn.1673-4157.2018.04.015]
点击复制

晚期糖基化终末产物与多囊卵巢综合征的关系()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
38
期数:
2018年04期
页码:
279-283
栏目:
基础研究
出版日期:
2018-07-20

文章信息/Info

Title:
Relationship between advanced glycation end-products and polycystic ovary syndrome
作者:
高四书 王龙 华飞
213003 常州,苏州大学附属第三医院内分泌科
Author(s):
Gao Sishu Wang Long Hua Fei
Department of Endocrinology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China
关键词:
晚期糖基化终末产物 多囊卵巢综合征 治疗
Keywords:
Advanced glycation end-products Polycystic ovary syndrome Treatment
DOI:
10.3760/cma.j.issn.1673-4157.2018.04.015
摘要:
晚期糖基化终末产物(AGEs)是高血糖的标志物,除参与衰老、糖尿病、动脉粥样硬化、女性不孕及肿瘤的发生外,还可促进多囊卵巢综合征(PCOS)相关特征的发生、发展。研究表明,AGEs可导致慢性炎性反应及氧化应激等,进而通过多种信号通路参与卵巢功能障碍、胰岛素抵抗、肥胖及非酒精性脂肪性肝病的发生,这可能是其对PCOS代谢和生殖方面发挥致病作用的机制。因此,抑制AGEs形成或阻断AGEs与其受体相互作用的药物可能对PCOS具有一定的治疗作用。
Abstract:
Advanced glycation end-products(AGEs)are markers of hyperglycemia and may contribute to the development of polycystic ovary syndrome(PCOS)-related features in addition to aging, diabetes, arteriosclerosis, female infertility and cancer. Studies have shown that AGEs-induced chronic inflammatory response and oxidative stress are involved in the pathogenesis of ovarian dysfunction, insulin resistance, obesity and nonalcoholic fatty liver disease through a variety of signaling pathways, which may play a pathogenic role in PCOS metabolism and reproduction mechanism.Therefore,inhibition of AGEs formation or blokade of AGEs binding to receptor for AGEs may have a certain therapeutic effect on PCOS.

参考文献/References:


[1] Rutkowska AZ, Diamanti-Kandarakis E. Do advanced glycation end products(AGEs)contribute to the comorbidities of polycystic ovary syndrome(PCOS)[J].Curr Pharm Des,2016,22(36):5558-5571.
[2] 曹琳,杨昱,刘超.减重手术对多囊卵巢综合征的治疗作用 [J].国际内分泌代谢杂志,2014,34(6):415-417.DOI:10.3760/cma.j.issn.1673-4157.2014.06.015.
[3] Merhi Z.Advanced glycation end products and their relevance in female reproduction[J].Hum Reprod,2014,29(1):135-145.DOI:10.1093/humrep/det383.
[4] Palimeri S,Palioura E,Diamanti-Kandarakis E.Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management[J].Diabetes Metab Syndr Obes,2015,8:415-426. DOI:10.2147/DMSO.S63089.
[5] Diamanti-Kandarakis E,Christakou C,Marinakis E.Phenotypes and enviromental factors:their influence in PCOS[J].Curr Pharm Des,2012,18(3):270-282.
[6] Diamanti-Kandarakis E,Piperi C,Kalofoutis A,et al.Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome[J].Clin Endocrinol(Oxf),2005,62(1):37-43.DOI:10.1111/j.1365-2265.2004.02170.x.
[7] Tantalaki E,Piperi C,Livadas S,et al.Impact of dietary modification of advanced glycation end products(AGEs)on the hormonal and metabolic profile of women with polycystic ovary syndrome(PCOS)[J].Hormones(Athens),2014,13(1):65-73.
[8] Liao Y,Huang R,Sun Y,et al.An inverse association between serum soluble receptor of advanced glycation end products and hyperandrogenism and potential implication in polycystic ovary syndrome patients[J].Reprod Biol Endocrinol,2017,15(1):9.DOI:10.1186/s12958-017-0227-8.
[9] Garg D,Merhi Z.Relationship between advanced glycation end products and steroidogenesis in PCOS[J].Reprod Biol Endocrinol,2016,14(1):71.DOI:10.1186/s12958-016-0205-6.
[10] Kandaraki E,Chatzigeorgiou A,Piperi C,et al.Reduced ovarian glyoxalase-Ⅰ activity by dietary glycotoxins and androgen excess: a causative link to polycystic ovarian syndrome[J].Mol Med,2012,18:1183-1189.DOI:10.2119/molmed.2012.00293.
[11] Baye E,Kiriakova V,Uribarri J,et al.Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: meta-analysis of randomised controlled trials[J].Sci Rep,2017,7(1):2266.DOI:10.1038/s41598-017-02268-0.
[12] Cai W,Ramdas M,Zhu L,et al.Oral advanced glycation endproducts(AGEs)promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1[J].Proc Natl Acad Sci U S A,2012,109(39):15888-15893.DOI:10.1073/pnas.1205847109.
[13] Chatzigeorgiou A,Kandaraki E,Piperi C,et al.Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats[J].J Endocrinol,2013,218(3):331-337.DOI:10.1530/JOE-13-0175.
[14] Fabre NT,Thieme K,Silva KS,et al.Hormetic modulation of hepatic insulin sensitivity by advanced glycation end products[J].Mol Cell Endocrinol,2017,447:116-124.DOI:10.1016/j.mce.2017.02.035.
[15] Angoorani P,Ejtahed HS,Mirmiran P,et al.Dietary consumption of advanced glycation end products and risk of metabolic syndrome[J].Int J Food Sci Nutr,2016,67(2):170-176.DOI:10.3109/09637486.2015.1137889.
[16] Sayej WN,Knight Iii PR,Guo WA,et al.Advanced glycation end products induce obesity and hepatosteatosis in CD-1 wild-type mice[J].Biomed Res Int,2016,2016:7867852.DOI:10.1155/2016/7867852.
[17] Jia X,Chang T,Wilson TW,et al.Methylglyoxal mediates adipocyte proliferation by increasing phosphorylation of Akt1[J].PLoS One,2012,7(5):e36610. DOI:10.1371/journal.pone.0036610.
[18] Mahali SK,Verma N,Manna SK.Advanced glycation end products induce lipogenesis: regulation by natural xanthone through inhibition of ERK and NF-κB[J].J Cell Physiol,2014,229(12):1972-1980.DOI:10.1002/jcp.24647.
[19] Gaens KH,Goossens GH,Niessen PM,et al.Nε-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance[J].Arterioscler Thromb Vasc Biol,2014,34(6):1199-1208.DOI:10.1161/ATVBAHA.113.302281.
[20] Mastrocola R,Collino M,Nigro D,et al.Accumulation of advanced glycation end-products and activation of the SCAP/SREBP lipogenetic pathway occur in diet-induced obese mouse skeletal muscle[J].PLoS One,2015,10(3):e0119587.DOI:10.1371/journal.pone.0119587.
[21] Dozio E,Briganti S,Delnevo A,et al.Relationship between soluble receptor for advanced glycation end products(sRAGE), body composition and fat distribution in healthy women[J].Eur J Nutr,2017,56(8):2557-2564.DOI:10.1007/s00394-016-1291-0.
[22] Targher G,Rossini M,Lonardo A.Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis [J].Endocrine,2016,51(2):211-221.DOI:10.1007/s12020-015-0640-8.
[23] 李博,苏青.晚期糖基化终末产物及其受体与非酒精性脂肪性肝病的关系 [J]. 国际内分泌代谢杂志,2017,37(3):192-194.DOI:10.3760/cma.j.issn.1673-4157.2017.03.013
[24] Rocha ALL,Faria LC,Guimaraes TCM,et al.Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic reviewand meta-analysis[J].J Endocrinol Invest,2017,40(12):1279-1288.DOI:10.1007/s40618-017-0708-9.
[25] Vassilatou E,Vassiliadi DA,Salambasis K,et al.Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease[J].Eur J Endocrinol,2015,173(6):739-747.DOI:10.1530/EJE-15-0567.
[26] Garg D,Merhi Z.Advanced glycation end products: link between diet and ovulatory dysfunction in PCOS [J].Nutrients,2015,7(12):10129-10144.DOI:10.3390/nu7125524.
[27] Park JH,Choi TS.Polycystic ovary syndrome(PCOS)-like phenotypes in the d-galactose-induced aging mouse model[J].Biochem Biophys Res Commun,2012,427(4):701-704.DOI:10.1016/j.bbrc.2012.09.099.
[28] 杨昱,刘超.2013年美国内分泌学会多囊卵巢综合征诊疗指南解读 [J]. 中华内分泌代谢杂志,2014,30(2):89-92.DOI:10.3760/cma.j.issn.1000-6699.2014.02.001.
[29] Diamanti-Kandarakis E,Alexandraki K,Piperi C,et al.Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome[J].Metabolism,2007,56(1):129-134.DOI:10.1016/j.metabol.2006.09.006.
[30] Christakou C,Kollias A,Piperi C,et al.The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers[J].Hormones(Athens),2014,13(4):488-497.DOI:10.14310/horm.2002.1553.
[31] Diamanti-Kandarakis E,Piperi C,Alexandraki K,et al.Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome[J].Metabolism,2006,55(4):494-500.DOI:10.1016/j.metabol.2005.10.011.
[32] Diamanti-Kandarakis E,Katsikis I,Piperi C,et al. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome[J].Clin Endocrinol(Oxf),2007,66(1):103-109.DOI:10.1111/j.1365-2265.2006.02693.x.
[33] Irani M,Minkoff H,Seifer DB,et al.Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS[J].J Clin Endocrinol Metab,2014,99(5):E886-E890.DOI:10.1210/jc.2013-4374.

相似文献/References:

[1]黄爱洁,周莹,符金香,等.青春期多囊卵巢综合征的诊治进展[J].国际内分泌代谢杂志,2016,36(05):338.[doi:10.3760/cma.j.issn.1673-4157.2016.05.14]
 Huang Aijie,Zhou Ying,Fu Jinxiang,et al.Diagnosis and treatment of polycystic ovary syndrome in adolescence[J].International Journal of Endocrinology and Metabolism,2016,36(04):338.[doi:10.3760/cma.j.issn.1673-4157.2016.05.14]
[2]李博,苏青.晚期糖基化终末产物及其受体与非酒精性脂肪性肝病的 关系[J].国际内分泌代谢杂志,2017,37(03):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
 Li Bo,Su Qing..Relationship between advanced glycation end-products and its receptor in nonalcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2017,37(04):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
[3]叶凌霞 洪洁.多囊卵巢综合征与肠道菌群[J].国际内分泌代谢杂志,2019,39(05):345.[doi:10.3760/cma.j.issn.1673-4157.2019.05.014]
 Ye Lingxia,Hong Jie.Polycystic ovary syndrome and gut microbiota[J].International Journal of Endocrinology and Metabolism,2019,39(04):345.[doi:10.3760/cma.j.issn.1673-4157.2019.05.014]
[4]牟靖 谈宗国 吴萍.miRNA-320及其靶基因内皮素-1与多囊卵巢 综合征易感性及临床特点的关系研究[J].国际内分泌代谢杂志,2020,40(02):87.[doi:10.3760/cma.j.issn.1673-4157.2020.02.004]
 Mou Jing,Tan Zongguo,Wu Ping.Relationship between miRNA-320, its target gene endothelin-1 and the susceptibility and clinical features of polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2020,40(04):87.[doi:10.3760/cma.j.issn.1673-4157.2020.02.004]
[5]高飞,董旋,徐倩倩,等.AGEs对大鼠骨髓间充质干细胞成骨分化中β-catenin、ALP的影响及PTH的干预作用[J].国际内分泌代谢杂志,2021,41(03):173.[doi:10.3760/cma.j.cn121383-20210225-02059]
 Gao Fei,Dong Xuan,Xu Qianqian,et al.Effects of AGEs on β-catenin and ALP in osteogenic differentiation of rat bone marrow mesenchymal stem cells and the intervention of PTH[J].International Journal of Endocrinology and Metabolism,2021,41(04):173.[doi:10.3760/cma.j.cn121383-20210225-02059]
[6]何沙沙,张洁,管璐璐,等.食源性晚期糖基化终末产物对肠道菌群及代谢相关疾病的影响研究进展[J].国际内分泌代谢杂志,2023,43(01):10.[doi:10.3760/cma.j.cn121383-20220131-01060]
 He Shasha,Zhang Jie,Guan Lulu,et al.Research progress on the effects of dietary advanced glycation end products on intestinal flora and metabolic disease[J].International Journal of Endocrinology and Metabolism,2023,43(04):10.[doi:10.3760/cma.j.cn121383-20220131-01060]
[7]蔡美丽,张曼娜,曲伸.代谢手术对肥胖女性生殖内分泌系统疾病影响的研究进展[J].国际内分泌代谢杂志,2023,43(06):469.[doi:10.3760/cma.j.cn121383-20230830-08071]
 Cai Meili,Zhang Manna,Qu Shen..Research progress on the impact of metabolic surgery on reproductive endocrine system diseases in obese women[J].International Journal of Endocrinology and Metabolism,2023,43(04):469.[doi:10.3760/cma.j.cn121383-20230830-08071]

备注/Memo

备注/Memo:
基金项目:常州市应用基础研究(CJ20159019); 常州市卫生人才培养工程资助(2016ZCLJ020)
通信作者:华飞,Email:czhuafei@vip.sina.com
更新日期/Last Update: 2018-04-30